Tumor Irradiation for Preclinical Studies

EPO has successfully conducted numerous customer-driven irradiation studies, demonstrating the effectiveness of our radiation therapy models. Our irradiator delivers controlled dosimetry, ensuring reproducible treatment conditions for reliable study outcomes. This system offers versatile applications, supporting both localized and whole-body irradiation studies. With established preclinical experience spanning decades.

X-Ray Irradiation System

• Faxitron MultiRad 160 X-Ray System: Enables irradiation of animals or cells.
• Irradiation Schedules: Simulate irradiation schedules during the drug discovery process.
• Dose Rates: Irradiate animals or cells at clinically relevant dose rates (up to 300 Gy/min) in a uniform or local field.

Advanced Applications of Radiation Therapy

• Therapeutic Radiation: Evaluate the effects of radiation on tumor cell proliferation.
• Myeloablation: Radiation of immunocompromised mice for supporting human tumor, stroma, and stem cell engraftment.
• Combination Therapy: Radiation therapy combined with chemotherapy, targeted therapies, and immunotherapy.
• Radiation Sensitivity of HNSCC PDX: Evaluation of radiochemo or radioimmuno combinations.

Enhancing Our Radionuclide / Radioimmunotherapy Capabilities

EPO is delighted to announce the launch of new facility capabilities for radionuclide therapy applications. Radioimmunotherapy in preclinical cancer models has a long history at EPO, and we are already approved for many frequently used radioactive isotopes (new approval requests available).

New Radionuclide Configuration Includes:

• Wizard 1480 Gamma-Counter from PerkinElmer
• ISOMED 2010 Dose Calibrator from Nuviatech Healthcare

Both instruments enable highly sophisticated study designs for biodistribution studies and efficacy trials. Precise assessment of organ and tumor activity after dosing with radionuclide compounds is now available to support projects aimed at developments in nuclear medicine.

For more details or to discuss potential collaborations, please contact Turn on Javascript!?subject=Newsletter%20Epo%20GmbH" target="_blank" title="Email-Dr. Dennis Gürgen">Dr. Dennis Gürgen. We look forward to advancing your oncology research with our expanding radiation therapy portfolio.

Best regards,

Jens Hoffmann & Wolfgang Walther

CEO & CSO at EPO Berlin-Buch